InvestorsHub Logo
Followers 47
Posts 12007
Boards Moderated 0
Alias Born 09/12/2017

Re: None

Monday, 07/06/2020 3:43:01 PM

Monday, July 06, 2020 3:43:01 PM

Post# of 232191
Awww, 9:09AM analyst says- CytoDyn "WORSENED PALPABLY"

We believe the risk/reward ratio has worsened palpably, since many open questions remain, including whether leronlimab could lower the mortality rate among severely ill patients in a controlled trial and if the drug is capable of generating clinically meaningful benefits among mild-to-moderate patients
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News